As therapeutic approach to interrupt the LysoPC - LPA axis, an oral inhibitor of autotaxin (GLPG1690) is currently evaluated in a Phase 2 study for IPF patients [57, 58]. This evidence concerns the gene ENPP2 and idiopathic pulmonary fibrosis.